Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 467

1.

Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.

Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, Shenoy S.

Pediatr Blood Cancer. 2008 Apr;50(4):822-5.

PMID:
17570702
2.

Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.

El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP.

J Pediatr. 2007 Apr;150(4):376-82.

PMID:
17382113
3.

B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.

Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R.

Haematologica. 2002 Feb;87(2):189-95. Erratum in: Haematologica 2002 Mar;87(3):336.

4.

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.

Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F.

Blood. 2003 May 15;101(10):3857-61. Epub 2003 Jan 16.

5.

Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children.

Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K.

Pediatr Nephrol. 2009 Jul;24(7):1321-8. doi: 10.1007/s00467-009-1191-0. Epub 2009 May 7.

PMID:
19421786
6.

B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.

Kumar S, Benseler SM, Kirby-Allen M, Silverman ED.

Pediatrics. 2009 Jan;123(1):e159-63. doi: 10.1542/peds.2008-2361. Epub 2008 Dec 15.

PMID:
19074962
7.

Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D.

Rheumatology (Oxford). 2006 Nov;45(11):1432-6. Epub 2006 Apr 21.

PMID:
16632482
8.

Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.

Schweizer C, Reu FJ, Ho AD, Hensel M.

Ann Hematol. 2007 Oct;86(10):711-7. Epub 2007 Jul 11.

PMID:
17622529
9.

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.

Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.

Am J Hematol. 2005 Apr;78(4):275-80.

10.

B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.

Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D.

Clin Otolaryngol. 2009 Aug;34(4):328-35. doi: 10.1111/j.1749-4486.2009.01968.x.

PMID:
19673980
11.

Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.

Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, Soldano F, Isola M, De Luca S, Fanin R.

Eur J Haematol. 2008 Sep;81(3):165-9. doi: 10.1111/j.1600-0609.2008.01100.x. Epub 2008 May 27.

PMID:
18510702
13.

Abbreviated dose rituximab for immune-mediated hematological disorders.

Fairweather H, Tuckfield A, Grigg A.

Am J Hematol. 2008 Jul;83(7):554-7. doi: 10.1002/ajh.21143.

14.
15.

Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.

Parodi E, Nobili B, Perrotta S, Rosaria Matarese SM, Russo G, Licciardello M, Zecca M, Locatelli F, Cesaro S, Bisogno G, Giordano P, De Mattia D, Ramenghia U.

Int J Hematol. 2006 Jul;84(1):48-53.

PMID:
16867902
16.

A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.

Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, Nakashima H, Muta K, Abe Y, Kiyohara C, Ueda A, Nagasawa K, Yoshizawa S, Shimoda T, Harada M.

Rheumatology (Oxford). 2008 Jun;47(6):821-7. doi: 10.1093/rheumatology/ken071. Epub 2008 Apr 8.

PMID:
18397955
17.

Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.

Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, Ghanima W, Shammas FV, Tjønnfjord GE.

Blood. 2004 Apr 15;103(8):2925-8. Epub 2003 Dec 30.

18.

Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.

Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR; Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.

Ann Hematol. 2006 Jun;85(6):400-6. Epub 2006 Mar 21. Erratum in: Ann Hematol. 2006 Aug;85(8):558. Dosage error in article text.

PMID:
16550390
19.

Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment.

Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB.

J Pediatr. 2005 Feb;146(2):217-21.

PMID:
15689912
20.

B-cell compartment as the selective target for the treatment of immune thrombocytopenias.

Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini V, Tani M, Molinari AL, Baccarani M, Fanin R.

Haematologica. 2003 May;88(5):538-46.

Supplemental Content

Support Center